Sunho Biologics (HKSE:02898) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sunho Biologics's Free Cash Flow for the six months ended in Jun. 2024 was HK$-145.25 Mil. Sunho Biologics's Revenue for the six months ended in Jun. 2024 was HK$0.00 Mil. Therefore, Sunho Biologics's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Sunho Biologics's current FCF Yield % is -26.97%.

The historical rank and industry rank for Sunho Biologics's FCF Margin % or its related term are showing as below:

HKSE:02898' s FCF Margin % Range Over the Past 10 Years
Min: -75050.44 Med: -11038.86 Max: -2081.22
Current: -75050.44

During the past 2 years, the highest FCF Margin % of Sunho Biologics was -2081.22%. The lowest was -75050.44%. And the median was -11038.86%.

HKSE:02898's FCF Margin % is ranked worse than
97.8% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs HKSE:02898: -75050.44

Sunho Biologics FCF Margin % Historical Data

The historical data trend for Sunho Biologics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics FCF Margin % Chart

Sunho Biologics Annual Data

Trend

Dec22

Dec23

FCF Margin %

-2,081.22

-19,996.49

Sunho Biologics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24
FCF Margin %	-	-	-11,342.54	-

Competitive Comparison of Sunho Biologics's FCF Margin %

For the Biotechnology subindustry, Sunho Biologics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunho Biologics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunho Biologics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sunho Biologics's FCF Margin % falls into.

Sunho Biologics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sunho Biologics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-45.592	/	0.228
	=	-19,996.49 %

Sunho Biologics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-145.254	/	0
	=	%

Sunho Biologics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunho Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN

Website

http://www.sunho-bio.com.cn

Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

Executives

Sunho Fortune Investments Limited	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Zhang Feng	2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited	2101 Beneficial owner

Sunho Biologics Headlines

No Headlines